Medications

FDA approves Itvisma for spinal muscular atrophy

The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal muscular atrophy (SMA) in patients 2 years and older with confirmed mutation in the survival motor neuron ...

Arthritis & Rheumatism

New clinical guidelines address gap in Adult-onset Still's disease

Adult-onset Still's disease (AOSD) is a rare inflammatory disorder. Thanks to a new initiative, AOSD is now considered to be the adult counterpart of systemic juvenile idiopathic arthritis, but in both cases the cause is ...

page 26 from 40